Pulmonary Fibrosis: Causes, Symptoms, Diagnosis, and Treatment

How Pulmonary Fibrosis Develops

Pulmonary fibrosis usually begins with repeated injury to lung tissue. Instead of normal repair, the healing process becomes abnormal. Fibroblasts, the cells responsible for connective tissue production, deposit excessive collagen and other extracellular matrix components.

This abnormal repair leads to thickened and rigid lung tissue. As the interstitium becomes scarred, oxygen diffusion across the lung membrane becomes more difficult. Reduced oxygen transfer results in lower oxygen levels in the blood and increased effort during breathing.

Over time, the reduced oxygen supply can place additional strain on the heart and circulatory system. In advanced disease, complications such as pulmonary hypertension and right-sided heart failure may develop.

Symptoms

Symptoms often develop gradually and worsen as the disease progresses.

Common manifestations include:

• progressive shortness of breath, initially during physical activity and later even at rest

• persistent dry cough without mucus production

• fatigue and reduced physical endurance

• unintentional weight loss

• muscle or joint discomfort

• enlargement and rounding of the fingertips or toes, known as digital clubbing

In the early stages, symptoms may be subtle and mistaken for aging or reduced physical conditioning. As lung function declines, everyday activities such as walking, dressing, or speaking for extended periods may become difficult.

Causes

Pulmonary fibrosis may arise from environmental exposures, medical treatments, medications, or underlying diseases. In many patients more than one contributing factor may be present.

Occupational and environmental exposures

Repeated inhalation of harmful particles can damage lung tissue over time. Substances associated with lung fibrosis include:

• silica dust

• asbestos fibers

• metal dusts

• wood, coal, or grain dust

• mold spores

• bird or animal droppings

People working in mining, farming, construction, manufacturing, or animal handling may have higher exposure risk if protective measures are not used.

Radiation therapy

Radiation treatment directed at the chest, often used for lung or breast cancer, can cause delayed lung injury. Radiation-induced fibrosis may appear months or even years after treatment. The severity depends on radiation dose, the portion of lung exposed, and whether chemotherapy was used simultaneously.

Medication-related lung injury

Some medications can damage lung tissue and trigger fibrotic changes. Drugs associated with pulmonary toxicity include certain chemotherapy agents, antiarrhythmic medications such as amiodarone, and some antibiotics.

If medication-related fibrosis is recognized early and the drug is discontinued, progression may slow, although existing lung damage may persist.

Medical conditions linked to pulmonary fibrosis

Fibrosis can develop secondary to systemic diseases that produce chronic inflammation.

Conditions associated with lung fibrosis include:

• rheumatoid arthritis

• systemic lupus erythematosus

• scleroderma

• polymyositis and dermatomyositis

• mixed connective tissue disease

• sarcoidosis

• recurrent or severe pneumonia

Chronic immune activation in these disorders may gradually alter lung structure.

Idiopathic pulmonary fibrosis

In some patients no specific cause can be identified after thorough evaluation. This form, known as idiopathic pulmonary fibrosis, typically affects middle-aged and older adults.

Risk factors that appear associated with this condition include cigarette smoking, long-term exposure to air pollutants, genetic susceptibility, and gastroesophageal reflux disease. Some researchers suspect repeated microaspiration related to reflux may contribute to lung injury, although this relationship is still being studied.

Risk Factors

Several factors increase the likelihood of developing pulmonary fibrosis:

• current or past smoking

• occupational exposure to inhaled irritants

• cancer treatments involving radiation or chemotherapy

• autoimmune or connective tissue diseases

• family history of pulmonary fibrosis

Although uncommon, pulmonary fibrosis may also occur in children, usually due to genetic or developmental conditions.

Possible Complications

As pulmonary fibrosis progresses, serious complications may occur.

These may include:

• pulmonary hypertension caused by increased resistance in lung blood vessels

• right-sided heart failure resulting from long-term strain on the heart

• respiratory failure due to severe oxygen deficiency

• increased risk of lung cancer

• recurrent respiratory infections

• pneumothorax, or collapsed lung

Some patients experience acute exacerbations, episodes in which breathing suddenly worsens over a short period of days or weeks. These events require urgent medical care.

Diagnosis

Diagnosis involves integrating clinical information with imaging and functional testing.

Evaluation commonly includes:

• detailed medical and exposure history

• physical examination

• pulmonary function tests to assess lung capacity and gas exchange

• high-resolution computed tomography of the chest

• blood tests to identify autoimmune or inflammatory causes

In some cases, a lung biopsy may be necessary to confirm the diagnosis and determine the specific pattern of lung injury.

Treatment and Management

Although existing lung scarring cannot be reversed, treatment aims to slow disease progression and relieve symptoms.

Management strategies may include:

• antifibrotic medications that slow fibrotic progression

• supplemental oxygen therapy for low oxygen levels

• pulmonary rehabilitation programs to improve exercise tolerance

• treatment of underlying diseases such as autoimmune conditions or gastroesophageal reflux

• vaccination and preventive measures against respiratory infections

For patients with advanced disease who meet specific medical criteria, lung transplantation may offer a potential long-term treatment option.

When Medical Evaluation Is Needed

Persistent shortness of breath, chronic dry cough, or unexplained fatigue should be evaluated by a healthcare professional. Rapid worsening of breathing symptoms requires urgent medical attention, as it may indicate infection or an acute exacerbation of pulmonary fibrosis.

Early recognition allows earlier treatment and may improve long-term outcomes.

Selected Scientific References

King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. The Lancet. 2011;378(9807):1949–1961.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2018;198(5):e44–e68.

Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. New England Journal of Medicine. 2018;378:1811–1823.

Wells AU, Hirani N. Interstitial lung disease guideline. Thorax. 2008;63(Suppl V):v1–v58.

American Thoracic Society. Pulmonary fibrosis overview and management. ATS Clinical Practice Guidelines.